Sterling Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$87.4K Buy
4,337
+3,800
+708% +$102K ﹤0.01% 1496
2026
Q2
$13.6K Sell
537
-362
-40% -$7.96K ﹤0.01% 2068
2026
Q1
$20K Buy
899
+9
+1% +$215 ﹤0.01% 2028
2025
Q4
$23.8K Buy
890
+504
+131% +$12K ﹤0.01% 2134
2025
Q3
$8.24K Buy
386
+1
+0.3% +$24 ﹤0.01% 2595
2025
Q2
$8.3K Buy
385
+173
+82% +$3.22K ﹤0.01% 2245
2025
Q1
$3.52K Buy
212
+6
+3% +$109 ﹤0.01% 2329
2024
Q4
$3.78K Sell
206
-42
-17% -$678 ﹤0.01% 2577
2024
Q3
$3.81K Buy
+248
New +$4.14K ﹤0.01% 1868

Other funds holding ACAD

Sterling Capital Management's ACAD Position: Q3 2026 in Review

Sterling Capital Management increased its Acadia Pharmaceuticals (ACAD) stake by 708% in Q3 2026, buying an estimated $102K and bringing the position to 4,337 shares worth $87.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1496.

Sterling Capital Management first reported a position in ACAD in Q3 2024 and has held it in 9 quarters since. 351 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • Sterling Capital Management held 4,337 shares of Acadia Pharmaceuticals worth $87.4K as of Q3 2026.
  • Sterling Capital Management bought 3,800 Acadia Pharmaceuticals shares in Q3 2026, an estimated $102K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #1496 holding.
  • Sterling Capital Management first reported a position in Acadia Pharmaceuticals in Q3 2024 and has held it in 9 quarters since.
  • 351 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.